MicroRNA-146a 表达与乳腺癌临床分子亚型的 相关性研究

目的??检测 microRNA-146a（miR-146a）在不同临床分子亚型的乳腺癌组织中的表达，分析 miR- 146a 与分子亚型之间的相关性。方法??选取新疆医科大学第一附属医院乳腺浸润性导管癌患者手术标本 185 例， 应用原位杂交技术检测乳腺癌石蜡组织中 miR-146a 的表达情况，应用 χ 2 检验和秩和检验分析 miR-146a 表 达水平在不同临床分子亚型的乳腺癌之间的关系。结果??4 组不同临床分子亚型的浸润性乳腺癌组织中，miR- 146a 在 Lumina?A 型中的阳性表达率最高，而 miR-146a 在 basal-like 型的阴性表达率最高，临床分子亚型中 miR-146a 表达差异有统计学意义（ P < 0.05） ， 进一步分组检验， Lumina?A 型较 basal-like 型阳性表达率与 basal- like 型比较，差异有统计学意义（ P < 0.05） 。结论??miR-146a 在浸润性乳腺癌组织中的表达与其临床分子亚型相关，浸润性乳腺癌组织中 miR-146a 阳性表达程度高提示预后较佳，其有望成为乳腺癌新的预后分子判断 标志。

Expression of MicroRNA-146a in subtypes of breast cancer

Objective To investigate the expression of miR-146a in molecular subtypes. Methods Totally 185 cases of patients with breast invasive ductal cancer who were admitted into our hospital during Jan. 2013 to Aug 2016 were involved in this study. Breast cancer tissue were collected during surgery. Expression levels of miR-146a was quantified by hybridization in situ method. Association of miR-146a with molecular subtypes of breast cancer was identified by Pearson chi-square test and Nemenyi Rank sum test. Results Among four subtypes in breast cancer, miR-146a had the highest expression rate in Lumina A type while lowest expression rate in basal-like type ( P < 0.05). Conclusions Expression of miR-146a is closely associated with molecular subtypes of breast cancer, which may be a new prognostic biomarker of breast cancer.